Journal article
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
Abstract
AimsTo estimate the incidence of major adverse cardiovascular events (MACE), expanded MACE, and MACE or Death across Fibrosis- 4 score (FIB-4) categories in people with type 2 diabetes and to determine whether efpeglenatide’s effect varies with increasing FIB-4 severity.Materials and methodsAMPLITUDE-O trial data were used to estimate the relationship of FIB-4 score categories to the hazard of MACE, expanded MACE, and MACE or death. …
Authors
Del Prato S; Li Z; Ramasundarahettige C; Branch KRH; Lam CSP; Lopes RD; Pratley R; Rosenstock J; Sattar N; Gerstein HC
Journal
Cardiovascular Diabetology, Vol. 23, No. 1,
Publisher
Springer Nature
DOI
10.1186/s12933-024-02432-7
ISSN
1475-2840